Serialization legislation has been introduced in a bid to eradicate counterfeit medicines from the pharmaceutical supply chain. The counterfeit medicines market is estimated to be worth around $200 billion annually, demonstrating that the cost and patient risk associated with these drugs is huge.
Dexter Tjoa, director of corporate strategy at Tjoapack, discusses the new serialization regulations and what they could mean for the industry as part of an expert roundtable in PharmaVOICE. He also outlines steps companies need to take beyond these initial regulations in order to make the supply chain as safe and secure as possible.
Read the full roundtable here: http://www.pharmavoice.com/article/2018-01-track-and-trace/